126
Participants
Start Date
November 15, 2022
Primary Completion Date
November 29, 2024
Study Completion Date
May 19, 2025
Cohort 1 in Part A
Dose 1 KAN-101 Intravenous (IV) infusion
Cohort 2 in Part A
Dose 2 KAN-101 Intravenous (IV) infusion
Placebo: Group 1 in Part B and Part C
Placebo Intravenous (IV) infusion
Group 2 in Part B and Part C
Dose 3 KAN-101 Intravenous (IV) infusion
Group 3 in Part B and Part C
Dose 4 KAN-101 Intravenous (IV) infusion
Group 4 in Part B and Part C
Dose 5 KAN-101 Intravenous (IV) infusion
Optimal Clinical Trials, Auckland
Campbelltown Hospital, Campbelltown
The Royal Melbourne Hospital, Parkville
P3 Research - Tauranga, Tauranga
Box Hill Hospital, Box Hill
Waikato Hospital, Hamilton
Wesley Research Institute, Auchenflower
Royal Adelaide Hospital, Adelaide
P3 Research - Palmerston North, Paraparaumu
P3 Research - Wellington, Wellington
St John of God Midland Public and Private Hospitals, Midland
P3 Research - Dunedin, Dunedin
Celiac Disease Center at Columbia University, New York
Penn State Milton S. Hershey Medical Center, Hershey
North Carolina Clinical Research, Raleigh
Agile Clinical Research Trials, Sandy Springs
GCP Research, St. Petersburg
University of Alabama at Birmingham, Birmingham
Vanderbilt University Medical Center, Nashville
Aventiv Research, Inc. d/b/a Centricity Research, Columbus
Great Lakes Gastroenterology Research, LLC, Mentor
Northshore Gastroenterology Research, LLC, Westlake
Indiana University Health University Hospital, Indianapolis
University of Iowa, Iowa City
Prism Research LLC dba Nucleus Network, Saint Paul
Mayo Clinic, Rochester
Rush University Medical Center, Chicago
Sneeze, Wheeze & Itch Associates, LLC, Normal
Washington University School of Medicine, St Louis
Quality Clinical Research, Omaha
Digestive Research of Central Texas, Waco
The University of Texas Health Science Center at Houston, Houston
Velocity Clinical Research, Salt Lake City, West Jordan
Advanced Research Institute, Ogden
Anaheim Clinical Trials, LLC, Anaheim
PCRN Trials, Takapuna
Collaborators (1)
Pfizer
INDUSTRY
Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA
INDUSTRY